US clears paediatric use of GSK’s Arnuity Ellipta
GlaxoSmithKline’s inhaled corticosteroid Arnuity Ellipta has been approved in the US for paediatric use.
Read Moreby Selina McKee | May 22, 2018 | News | 0
GlaxoSmithKline’s inhaled corticosteroid Arnuity Ellipta has been approved in the US for paediatric use.
Read Moreby Selina McKee | Apr 25, 2018 | News | 0
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
Read Moreby Selina McKee | Mar 9, 2018 | News | 0
The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach.
Read Moreby Selina McKee | Sep 19, 2017 | News | 0
GlaxoSmithKline and Innoviva have bagged a green light in the US for the novel triple therapy inhaler Trelegy Ellipta, opening the door to a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read Moreby Selina McKee | May 8, 2017 | News | 0
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
Read Moreby Selina McKee | Sep 7, 2016 | News | 0
GlaxoSmithKline and Innoviva’s three-drug inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has come out on top in a trial assessing its effectiveness against the dual therapy Symbicort Turbohaler in patients with chronic obstructive pulmonary disorder (COPD).
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479